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Abstract 
Approximately one third of the world’s 15000 
accelerators are used for tumour therapy and other 
medical applications [1]. The characteristics of FFAGs 
make them ideally suited to such applications, as the 
much smaller magnet size and greater compactness offers 
considerable cost and operational benefits. In the first 
stage the work on PAMELA will focus on the 
optimization of the FFAG design to deliver the specific 
machine parameters demanded by therapy applications. In 
this phase of the PAMELA project the effort will 
concentrate on the design of a semi-scaling type FFAGs 
to deliver a 450 MeV/u carbon ion beam, including 
detailed lattice and tracking studies. The second stage will 
use the existing expertise in the BASROC consortium [2] 
to undertake a design of the magnets and RF system for 
PAMELA. An outline of the overall concept of PAMELA 
will be discussed and the actual status of the work will be 
presented. 
INTRODUCTION 
There has also been a recent, very strong interest in 
using NS-FFAGs for cancer therapy, as the much smaller 
magnet size and greater compactness would add both cost 
and operational benefits, in particular the ease of 
delivering a beam at any energy. Some initial simulation 
work has been done, the most advanced by a small 
collaboration led by the Brookhaven National Laboratory 
[3]. This envisages a proton and carbon ion complex 
consisting of an RFQ and short linac, and then three rings. 
Both proton and carbon ions are accelerated in the linac. 
The protons are then accelerated to 31 and 250 MeV in 
the first two rings and carbon to 69 and 400 MeV/u in the 
second and third. The rings are 35, 43 and 52m in 
circumference, respectively, and the largest horizontal 
magnet aperture, in the third ring, is less than 40mm.  
While the main properties of FFAG’s are ideal suited 
for medical applications there are still some serious issues 
to be solved before building such a machine. The main 
challenge for the use of NS-FFAG is the resonance 
crossing acceleration. The lattice of NS-FFAG usually 
consists of linear magnet. The simplicity and flexibility 
coming from this are the advantages of NS-FFAG. 
However, due to the nature of a linear lattice, it inevitably 
encounters many resonances during acceleration. 
Nevertheless, there is considerable concern that the 
resonances will have a much too severe effect on the 
beam to make this a viable option. This will be 
investigated by EMMA, which is to build a 20MeV 
electron NS-FFAG as a proof-of-principle machine [5]. 
In PAMELA, the accelerated beams are non-relativistic 
proton or heavy ions. Therefore, though the feasibility of 
NS-FFAG with resonance crossing acceleration is 
established in EMMA, considerable additional design 
work is required especially for lattice design and 
acceleration scheme in PAMERA, where the acceleration 
process is much slower compared with EMMA. 
Additionally the problem of beam injection and extraction 
into and from the different rings is another challenge in 
PAMELA. 
The first stage of this work will be the design of 
machines to deliver a 450 MeV/u carbon ion beam with 
small or zero tune variations. This will include detailed 
lattice and tracking studies. The second phase will be to 
use the existing expertise in the consortium to undertake a 
design of the magnets and RF system for this machine. 
The output from these stages will be a demonstration of 
feasibility. The third phase will be a preliminary cost 
estimate for the complex, allowing comparison with 
existing technologies on performance and cost. 
The next stage will be to take the work done and to 
scale the design down to both 70 MeV and 230 MeV 
proton machines as possible prototypes, including cost 
estimates. The second of these machines would be 
preferable as not only could it be developed into a therapy 
machine, it could also be used to produce 68 MeV/u 
carbon ions. 
As there is a lack of evidence demonstrating the 
benefits of carbon over protons, this machine would be 
used to “treat” mice to obtain this. In addition, it would 
provide scientifically obtained evidence demonstrating 
the benefits of hadron therapy over standard radiotherapy. 
If the higher energy machine proves to be too expensive, 
however, the lower energy machine could be used both as 
a NS-FFAG prototype and also to do the comparison 
between hadron and radiotherapy. 
BEAM PARAMETERS REQUIRED FOR A 
CANCER THERAPY MACHINE 
In a first step, a list of beam parameters as required for 
a hadron therapy machine has been discussed and agreed 
on. The beam energy of the protons should be tuneable in 
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the range between 50 and 270 MeV (up to 325 MeV for 
proton radiography) and for carbon a beam energy up to 
450 MeV/nucleon is required. 
For the treatment with protons a dose of 2 Gray/minute 
in a volume of 2 litres (protons) will be the goal. One 
should note that the dose given refers to the radiation 
deposited in the tumour. The dose is (almost) independent 
of the incident energy of the proton. The residual range 
when the Bragg peak starts is about 5cm. Taking the 
irradiated tissue as water, this corresponds in the standard 
“Range/Mass versus Momentum/Mass” tables to a βγ of 
about 4, or a proton momentum of about 0.3 GeV/c, or a 
proton energy of around 45 MeV. Taking this into 
account a dose of 2 Gray/minute would require ~1.35 × 
1013 MeV of proton energy deposited per minute at 45 
MeV/proton. This gives a proton flux of 3×1011 protons 
per second, or a average current of 50 nA.  
The requirement for the dose calibration is that the dose 
deposition in a 5 mm × 5 mm × 5mm cube (125 mm3) is 
controlled to within 5%. This implies (assuming 100 
pulses) that the individual pulses are controlled and 
known at the level of 50%, which is a major advantage of 
an rapid cycling machine for such purposes. The 
maximum field to be irradiated should be of 40 cm × 40 
cm in size and the penetration depth will be (depending 
on the beam energy) up to 25 cm. The spot size of the 
beam in the tumour should be below 1 cm. For raster 
scanning, the requirement is to perform 60 “spills” in 
about 2-3 minutes, which is defined by the maximum 
time the patient can be expected to be “still”. This 
requires changing the penetration depth and therefore the 
speed of the energy scanning to be at the Hz level (~0.1-1 
Hz). The number of energy steps will probably be limited 
by the machine. From a clinical point of view, the energy 
steps should be small compared with the size of the Bragg 
peak (45 MeV see above, so 5-10 MeV). However, the 
machine is likely to deliver an energy step of a few 
hundred keV/turn, so that the granularity of the energy 
steps should not be of concern. 
The energy spread allowed for the machine is related to 
the straggling of the ions in the tissue. A proton with 
energy 250 MeV with straggling ~2.5% has a kinetic 
energy spread (full width) of about 10-15 MeV. If we do 
not want the energy spread of the machine to dominate 
over the straggling, we need to keep the energy spread on 
the beam at 250 MeV to be less than 5 MeV, or 2% (~4% 
on momentum). The main requirements of a hadron 
therapy machine are summarized in table 1. 
Table 1: Summary of Beam Parameters for an FFAG 
Based Hadron Cancer Therapy Facility PAMELA 
 protons carbon 
Beam energy (MeV/u) <325 <450 
Energy step size (MeV/u) ~10 ~10 
Beam current (enA) 50 3 
Particle flux (1/sec) 3×1011 3×1009 
THE FRONT END 
Two different scenarios for the Front End are under 
discussion both with different advantages and 
disadvantages. While the first one requires no change in 
the field power of the dipole for operation with both 
species at the price of a lower proton current, the other 
needs adjustment of the FFAG dipoles when changing the 
species making a fast switching difficult. 
In the first scenario a commercially available small 
cyclotron with an output energy of 4 MeV will be used to 
inject a proton beam into the FFAG (see figure 1). In this 
first phase this beam could be accelerated to the final 
energy of 350 MeV using two FFAGs, allowing various 
oncology studies and proton therapy. In the second phase 
of the project a carbon injector consisting of an ECR ion 
source, an LEBT utilizing a spectrometer for mass/charge 
separation and an RFQ (beam energy at the output of the 
RFQ will be 1 MeV/u, see second scenario) will be added 
together with a third FFAG to allow treatment with 
carbon ions up to an energy of 450 MeV. 
 
Figure 1: Schematic drawing of the beam injector 
scenario 1. 
The second scenario is shown in figure 2. It will consist in 
the first phase of an ECR ion source delivering a beam 
current of 2mA of protons with 10 keV beam energy, in 
the second phase an additional ECR source will be added 
to deliver 0.2 mA of C4+ at 120 keV beam energy. The 
beam is injected into LEBT section consisting of 
solenoids for beam focussing and set up as a spectrometer 
line utilizing a magnetic dipole for charge/mass 
separation followed by an RFQ running at about 200 
MHz. 
 
Figure 2: Schematic drawing of the beam injector 
scenario 2. 
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The RFQ itself will be approximately 2.5 m long and 
requires 300 kW of RF power. It will accelerate the beam 
to an energy of 1 MeV/u. The beam parameters at RFQ 
output are summarized in Table 2. 
Table 2: Output Parameters for Beam Injector Scenario 1 
and 2 
 Protons scenario 1 (2) C4+ 
peak Current (mA) <0.1 (>2) ~0.2 
ε100%,n (π*mm*mrad) 0.4-0.6   
εRMS,n (π*mm*mrad) 0.1-0.15   
RF Frequency (MHz) ~200   
Bunch length (ps) ~500   
Pulse length (ms) ~100   
Repetition rate (Hz) ~1000   
Particles per bunch # 106-107 (107-108) 105-106 
Beam energy (MeV/u) 4 (1) 1 
Behind the RFQ a MEBT beam line consisting of RF 
bunching cavities and magnetic quadrupoles for 
transversal and longitudinal beam focussing to adopt the 
RFQ output parameters to the required FFAG injection 
parameters. Additionally a stripping foil will be used to 
increase the charge state of the carbon ions from 4+ to 6+ 
to increase the acceleration efficiency in the FFAG rings. 
The position of the stripping foil is still under discussion 
but between the first and second FFAG is most likely, as 
the stripping efficiency will be much higher compared 
with stripping behind the RFQ. 
FFAG LAYOUT 
One of the advantages of NS-FFAG for a particle 
therapy facility is flexibility in facility operation. Due to 
the fixed field, just by changing the injection particle, it 
can immediately change the delivering particle. 
The planned facility aims to deliver proton and heavy 
ion beam for treatment. Thus, considering the injector 
energy and reasonable momentum range of one NS-
FFAG ring, which is typically about factor of 3, the 
facility is to consist of three cascaded rings. The beam 
parameters are summarized in Table 3. The second ring 
works as the final ring for proton therapy and the booster 
for the final carbon ring as well. 
BEAM DELIVERY AND GANTRY 
The fast beam extraction of a FFAG accelerator allows 
it to deliver beams to multiple ports simultaneously. It is a 
unique feature of FFAG as an accelerator for particle 
therapy and it drastically improves efficiency of a 
treatment facility. The beam structure is pulsed one, 
which is well fitted to the spot scanning irradiation, but it 
needs consideration in employing the board beam with a 
wobbler. 
Table 3: Parameters of Accelerator Complex 
Proton 
Injector 1 
Injection 
(MeV) 
Extraction 
(MeV,max) 
Momentum 
ratio 
1st ring 4 40 3.2 
2nd ring 40 350 3.2 
Proton 
Injector 2 
   
1st ring 1 10 3.2 
2nd ring 10 100 3.2 
3rd ring 100 350 1.9 
Carbon6+    
1st ring 1 10 3.2 
2nd ring 10 100 3.2 
3rd ring 100 450 3.1 
For the rotating gantry, an ordinary gantry as developed 
for existing facilities can be used as long as the energy 
changing rate is slow (typically several times/sec) 
However, if a much faster change in energy, for instance 
as fast as the repetition rate of FFAG, is required, another 
approach such as FFAG gantry proposed by [6] must be 
taken. 
SUMMARY 
While the PAMELA project has just started and the 
team is still under formation, the main parameters 
required to built a machine for oncology studies as a first 
step, and to extend this machine finally to a full hadron 
cancer therapy machine based on 3 FFAGs, have been 
defined. Within the 3 years of the study a robust design 
based also on the experiences gained from the 
commissioning of EMMA is expected. 
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